leisure time -WSS

leisure time

author：entertainment 2025-09-28 18:30:37 - browse：39245

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Why getting cancer drugs just got harder for rural patients

focus

WSS

CDC launches VaccineFinder tool to locate Covid

Lessons Learned: This is why you network to find that industry job you want

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Astronauts get first look at the spacecraft that will fly them around the moon

Former Georgia lieutenant governor says he received grand jury subpoena

AstraZeneca loses challenge to Medicare drug price negotiation

entertainment

leisure time

focus

What does generative AI mean for health care? We asked experts

FDA does about

Sports medicine is finally prioritizing gender equality

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Guidelines to prevent youth baseball injuries need more muscle

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

BioMarin wins approval for gene therapy to treat hemophilia A

Sage's campaign to raise awareness of postpartum depression hits a nerve

Dobbs anniversary: the lost opportunity of abortion as health care

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

entertainment

Biotech companies concerned about China biosecurity crackdown

Hospitals use virtual reality to design more inclusive rooms for kids

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Lessons Learned: This is why you network to find that industry job you want

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Wegovy cuts risk of cardiovascular events by 20%, study finds

explore

focus

entertainment

Wikipedia